PMID- 37348229
OWN - NLM
STAT- MEDLINE
DCOM- 20230726
LR  - 20230726
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 121
DP  - 2023 Aug
TI  - Aiming to IgE: Drug development in allergic diseases.
PG  - 110495
LID - S1567-5769(23)00818-4 [pii]
LID - 10.1016/j.intimp.2023.110495 [doi]
AB  - The incidence of allergic disease significantly increases in recent decades, 
      causing it become a major public health problem all over the world. The common 
      allergic diseases such as allergic dermatitis, allergy rhinitis, allergic asthma 
      and food allergy are mediated, at least in part, by immunoglobulin E (IgE), and 
      so IgE acts as a central role in allergic diseases. IgE can interact with its 
      high-affinity receptor (FcepsilonRⅠ) which is primarily expressed on tissue-resident 
      mast cells and circulating basophils, initiating intracellular signal 
      transduction and then causing the activation and degranulation of mast cells and 
      basophils. On the other hand, IgE interaction with its low-affinity receptor 
      (CD23), can regulate various IgE-mediated immune responses including IgE-allergen 
      complex presentation, IgE synthesis, the growth and differentiation of both B and 
      T cells, and the secretion of pro-inflammatory mediators. With the deeper 
      mechanism research for allergic diseases, new therapeutic strategies for 
      interfering IgE are developed and receive a great attention. In this review, we 
      summarize a current profile of therapeutic strategies for interfering IgE in 
      allergic diseases. Besides, we suggest that targeting memory B cells (including 
      long-lived plasma cells and (or) IgE(+) memory B cells) may help to completely 
      control allergic diseases, and highlight that the development of drugs 
      synergistically aiming to multiple targets can be a better choice for improving 
      treatment efficacy which results from allergic diseases as the systemic disorders 
      caused by an impaired immune system.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Ling, Xiao-Jing
AU  - Ling XJ
AD  - Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer 
      Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 
      China.
FAU - Wei, Ji-Fu
AU  - Wei JF
AD  - Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer 
      Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 
      China. Electronic address: weijifu@njmu.edu.cn.
FAU - Zhu, Ying
AU  - Zhu Y
AD  - Department of Blood Transfusion, Ganzhou Key Laboratory of Anesthesiology, 
      Anesthesia and Surgery Center, First Affiliated Hospital of Gannan Medical 
      University, Ganzhou, China. Electronic address: pink-shadow@gmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230620
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Receptors, IgE)
SB  - IM
MH  - Humans
MH  - Immunoglobulin E
MH  - *Rhinitis, Allergic
MH  - Basophils
MH  - *Asthma/drug therapy
MH  - Receptors, IgE
MH  - Drug Development
MH  - Mast Cells
OTO - NOTNLM
OT  - Allergy diseases
OT  - Challenge
OT  - Drug development
OT  - IgE
OT  - Therapeutic strategies
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/06/23 01:10
MHDA- 2023/07/26 06:43
CRDT- 2023/06/22 18:04
PHST- 2023/05/06 00:00 [received]
PHST- 2023/06/09 00:00 [accepted]
PHST- 2023/07/26 06:43 [medline]
PHST- 2023/06/23 01:10 [pubmed]
PHST- 2023/06/22 18:04 [entrez]
AID - S1567-5769(23)00818-4 [pii]
AID - 10.1016/j.intimp.2023.110495 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2023 Aug;121:110495. doi: 10.1016/j.intimp.2023.110495. Epub 
      2023 Jun 20.